43 results on '"Carteni, G."'
Search Results
2. S-TRAC adjuvant sunitinib phase 3 trial in patients with high risk renal cell carcinoma: Subgroups analyses by risk factors
3. Preliminary efficacy and safety data of nivolumab in never smoker patients with advanced squamous NSCLC: Experience from Italian sites participating in the Expanded Access Programme (EAP)
4. genitourinary tumours, non prostate Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)
5. Time to response (TTR) and early tumor shrinkage (ETS) in recurrent glioblastoma patients treated with bevacizumab: an exploratory analysis of the prospective randomized AVAREG (ML25739) phase II study
6. 2143 Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open-label phase 3B CONSIGN study
7. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
8. NI-26 * COMPARATIVE ANALYSIS OF THE RANO AND MACDONAD'S CRITERIA IN RECURRENT GLIOBLASTOMA TREATED IN THE RANDOMIZED PHASE II TRIAL AVAREG WITH BEVACIZUMAB OR FOTEMUSTINE.
9. AT-11 * FINAL RESULTS FROM THE RANDOMIZED PHASE II TRIAL AVAREG (ML25739) WITH BEVACIZUMAB (BEV) OR FOTEMUSTINE (FTM) IN RECURRENT GBM
10. Bone Metastases from Rcc are not Always Associated with a Poor Prognosis
11. Randomized Phase Ii Trial Avareg (Ml25739) with Bevacizumab (Bev) or Fotemustine (Ftm) in Recurrent Gbm: Final Results from the Randomized Phase Ii Trial
12. Anemia Point Prevalence in Patients Receiving Chemotherapy in 56 Centers in Italy and Austria
13. High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer
14. 5056 POSTER Analysis of Metastatic Breast Cancer Management Across Europe -the EOS Study (European Observatory & Survey)
15. Therapeutic management of metastatic breast cancer across Europe: European observatory and survey (EOS).
16. Brain and meningeal metastases (BMm) from castration-resistant prostate cancer (CRPC) in the era of docetaxel (DOC).
17. Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer
18. 29 FIRST LINE CHEMOTHERAPY WITH DOCETAXEL/GEMCITABINE/TRASTUZUMAB (GOIM 2611) IN PATIENT WITH ADVANCED BREAST CANCER HER-2 POS: A CASE REPORT OF EARLY AND PROLONGED RESPONSE
19. 54 EPIDEMIOLOGY OF THE NEUROENDOCRINE TUMORS DIAGNOSED IN THE CARDARELLI HOSPITAL: A RETRO-SPECTIVE SINGLE-INSTITUTION ANALYSIS OF 299 CASES
20. Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer
21. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer
22. Malignant peritoneal mesothelioma—Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent
23. 248 SUNITINIB IN PATIENTS (PTS) WITH OR WITHOUT PRIOR NEPHRECTOMY IN AN EXPANDED-ACCESS STUDY OF METASTATIC RENAL CELL CARCINOMA (MRCC)
24. 247 SUNITINIB IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS (PTS) WITH BRAIN METASTASES (METS): DATA FROM AN EXPANDED-ACCESS STUDY
25. Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma (mRCC)
26. Sunitinib in metastatic renal cell carcinoma (mRCC) patients (pts) with brain metastases (mets): data from an expanded access trial
27. Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC)
28. SAFETY AND EFFICACY OF SUNITINIB IN AN EXPANDED-ACCESS TRIAL OF METASTATIC RENAL CELL CARCINOMA (MRCC): UPDATED RESULTS AND SUBPOPULATION ANALYSIS
29. 6571 POSTER Open-label study of pemetrexed (P) alone or in combination with a platinum in patients (pts) with peritoneal mesothelioma (PM): results from the international expanded access program (EAP)
30. 4503 ORAL Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of safety and efficacy in an expanded access trial with subpopulation analysis
31. The Grid Resource Broker portal
32. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: A Southern Italy Cooperative Oncology Group phase II–III randomized trial
33. A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck
34. Cisplatin — epirubicin — paclitaxel (PET) weekly administration with G-CSF support in advanced breast cancer (ABC). A phase II study
35. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: A dose-finding study
36. A phase I study of cisplatin, methotrexate, levofolinic acid and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck
37. 744 Methotrexate, L-folinic acid and 5-fluorouracil in the treatment of advanced digestive tract carcinomas
38. Protracted infusion (PI) of 5-FU+FA in advanced colorectal cancer
39. Urinary metabolites of PGIα in patients with osteosarcoma
40. A phase II study of octreotide in metastatic advanced prostatic cancer (MAPC)
41. Sandostatin, a long acting somatostatin analogue, in the treatment of advanced metastatic prostatic cancer
42. Lonidamine Alone and in Combination with Other Chemotherapeutic Agents in the Treatment of Cancer Patients
43. Role of Glucagon in the Glucoregulatory Response to Insulin-Induced Hypoglycemia in the Rat
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.